Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company develops pharmaceutical products in the areas of neurology, dermatology, and branded generics. It offers Wellbutrin XL to treat depressive disorders and Xenazine to treat chorea associated with Huntington's disease. Other drugs include CeraVe to rebuild and repair skin barrier and Kinerase, a cosmetic product. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1960 and is headquartered in Montreal, Canada.
Valeant Pharmaceuticals Tops Estimates in Four Straight Quarters
Valeant Pharmaceuticals topped the Zacks Consensus Estimate in each of the last four quarters. The average beat has been $0.07.5 above the Zacks Consensus Estimate which works out to be an average beat of 9.2%. In the session following the earniings release has seen VRX move higher two times and lower two times in the last four reports. The average of these four moves is a decrease of 3.4%.
The largest positive price movement in the stock came the day after the company reported the September 2011 quarter. Valeant Pharmaceuticals meet the topline estimate of $570 million, a year over year increase of 174%. EPS of $0.62 was $0.05 higher than the $0.57 Zacks Consensus Estimate and the stock moved higher by more than 15%.
Follow Brian Bolan on twitter at @BBolan1
Valeant Pharmaceuticals Most Recent Reported Earnings
On May 3, 2012 Valeant Pharmaceuticals reported revenue of $856 million, about $55 million more than the Zacks Consensus Estimate and up from $565 million reported in year ago quarter, an increase of 55%. Earnings per share came in at $1.14, $0.17 higher than the Zacks Consensus Estimate of $0.97. The beat of 17.5% didn't do much for the stock as investors sold forcing the stock lower by 9.8% in the session following earnings.
Valeant Pharmaceuticals Sees Estimates Moving Higher
Valeant Pharmaceuticals has seen earnings estimates move higher following the recent positive earnings surprise. The Zacks Consensus Estimate for 2012 was as low as a loss of $4.00 in January 2012 and has since moved higher to $4.40.
Similarly, estimates for 2013 have moved from $4.58 to $4.82 over the same time frame.
Valuation
Valeant Pharmaceuticals has a very attractive valuation. While trailing twelve months PE multiple of 14x is great than the 11.8x industry average, the forward PE multiple of 10.7x is below that of the industry average at 11.8x. Price to book of 3.5x is in line what you would expect for a growth company, but is higher than the industry average of 1.9x. Similarly, a price to sales ration of 5.3x is much higher than the 1.9x industry average.
The Chart
A look at the price and consensus chart shows a stock that was ahead of estimates throughout most of 2010 and 2011. Earnings have only recently caught up with the stock, but earnings continue to grow. This implies that the stock will likely continue on a higher trend over the next several quarters. The large gap between 2011 and 2012 estimates is the type of growth the aggressive growth investors tend to look for. Valeant Pharmaceuticals is a Zacks #1 Rank (Strong Buy).
Brian Bolan is the Aggressive Growth Stock Strategist for Zacks.com. He is also the Editor in charge of the Zacks Home Run Investor service
Like Brian Bolan on Facebook